scholarly article | Q13442814 |
P50 | author | Jens Juul Holst | Q28373106 |
Jonatan Ising Bagger | Q58110286 | ||
Katrine B Hansen | Q59542885 | ||
Filip K Knop | Q59659637 | ||
P2093 | author name string | T Vilsbøll | |
P433 | issue | 7 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | insulin resistance | Q1053470 |
P304 | page(s) | 3309-3317 | |
P577 | publication date | 2010-04-21 | |
P1433 | published in | The Journal of Clinical Endocrinology and Metabolism | Q3186902 |
P1476 | title | Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects | |
P478 | volume | 95 |
Q38015162 | Advances in the epidemiology, pathogenesis, and management of Cushing's syndrome complications |
Q35769505 | Calorie Restriction and Matched Weight Loss From Exercise: Independent and Additive Effects on Glucoregulation and the Incretin System in Overweight Women and Men |
Q35744498 | Defects in GLP-1 response to an oral challenge do not play a significant role in the pathogenesis of prediabetes |
Q39212408 | Diabetes in Cushing Disease |
Q40147836 | Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia. |
Q94545107 | Dulaglutide improves glucocorticoid-induced hyperglycemia in inpatient care and reduces dose and injection frequency of insulin |
Q38007405 | Effects of glucocorticoids and exercise on pancreatic β-cell function and diabetes development |
Q51328766 | Endogenous amylin and glucagon-like peptide-1 concentrations are not associated with gastric emptying in critical illness. |
Q34721183 | Exenatide improves glucocorticoid-induced glucose intolerance in mice |
Q51346211 | Gastrointestinal factors contribute to glucometabolic disturbances in nondiabetic patients with end-stage renal disease. |
Q42576497 | Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. |
Q36506631 | Glucocorticoids and type 2 diabetes: from physiology to pathology |
Q33754087 | Impact of early versus late enteral nutrition on cell mediated immunity and its relationship with glucagon like peptide-1 in intensive care unit patients: a prospective study |
Q51363927 | Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. |
Q48308334 | Impaired secretion of active GLP-1 in patients with hypertriglyceridaemia: A novel lipotoxicity paradigm? |
Q38038655 | Impairment of GLP1-induced insulin secretion: role of genetic background, insulin resistance and hyperglycaemia |
Q41082128 | Influence of gastrointestinal factors on glucose metabolism in patients with cirrhosis |
Q48245873 | Insulin resistance and bone: a biological partnership |
Q36783856 | Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes |
Q36736473 | Nine months of combined training improves ex vivo skeletal muscle metabolism in individuals with type 2 diabetes |
Q38122004 | Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity. |
Q35760279 | Physiology of incretins in health and disease |
Q91121478 | Physiology of the Incretin Hormones, GIP and GLP-1-Regulation of Release and Posttranslational Modifications |
Q35849382 | SUMO downregulates GLP-1-stimulated cAMP generation and insulin secretion |
Q47834909 | Systematic-analysis of mRNA expression profiles in skeletal muscle of patients with type II diabetes: The glucocorticoid was central in pathogenesis |
Q38247488 | Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events. |
Q48278731 | The effect of 8 days of strict bed rest on the incretin effect in healthy volunteers |
Q38245233 | The role of glucagon on type 2 diabetes at a glance. |
Q35680897 | β-Cell Sensitivity to GLP-1 in Healthy Humans Is Variable and Proportional to Insulin Sensitivity |
Search more.